Nicholas "Nick" Holdreith, Ph.D.

Nicholas “Nick” Holdreith, Ph.D., is a technical specialist in Sterne Kessler’s Biotechnology & Chemical Practice Group, where he assists with the preparation and prosecution of U.S. and international patent applications. His background and technical area of expertise include cellular and molecular biology, immunology, and cell and gene therapies.

Nicholas received his Ph.D. in Cell and Molecular Biology from the University of Pennsylvania. His thesis work was focused on investigating the role of cytokine signaling in hematopoietic stem and progenitor cell homeostasis and function to improve their expansion for transplantation-based therapies. Specifically, Nicholas and his colleges demonstrated that inhibition of LNK (SH2B3) enhances cytokine signaling and robustly expands both healthy and Fanconi Anemia hematopoietic stem cells. Their work suggests the potential of adding LNK inhibition to improve hematopoietic stem cell transplant-based gene therapies for Fanconi Anemia and other bone marrow failure disorders.

Before starting his graduate work, Nicholas received his B.S. in Biology and Biological Anthropology from The George Washington University. There he worked on various research projects including the development of biomaterials for regenerative medicine and investigations into the mechanisms behind myofibril repair in the context of muscular dystrophies and dysferlinopathies.